Novartis reported $8.87B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
AbbVie USD 10.77B 4.2B Sep/2026
Amgen USD 13.19B 799M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bausch Health Companies USD 2.49B 660M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Canopy Growth CAD 336.62M 28.06M Jun/2026
Corcept Therapeutics USD 98.72M 12.32M Sep/2026
Drreddys Laboratories INR 13.29B 2.07B Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Glaxosmithkline GBP 2.93B 508M Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Merck USD 9.55B 2.7B Sep/2026
Novartis USD 8.87B 1.25B Sep/2026
Novartis USD 8.87B 1.99B Sep/2026
Perrigo USD 436.6M 36.9M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Phibro Animal Health USD 75.55M 14.13M Sep/2026
Prestige Brands USD 46.52M 42.61M Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sanofi EUR 6.35B 806M Jun/2026
Supernus Pharmaceuticals USD 175.88M 4.07M Sep/2026
Zoetis USD 1.33B 143M Sep/2026